WAVE Life Sciences Ltd
WVE6.960USD
+0.160+2.35%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
1.08BCap. mercado
PérdidaP/E TTM
Más Datos de WAVE Life Sciences Ltd Compañía
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Información de la empresa
Símbolo de cotizaciónWVE
Nombre de la empresaWAVE Life Sciences Ltd
Fecha de salida a bolsaNov 11, 2015
Director ejecutivoDr. Paul B. Bolno, M.D.
Número de empleados287
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección7 Straits View
Ciudad
Bolsa de valoresNASDAQ Global Market Consolidated
PaísSingapore
Código postal018936
Teléfono6562363388
Sitio Webhttps://www.wavelifesciences.com/
Símbolo de cotizaciónWVE
Fecha de salida a bolsaNov 11, 2015
Director ejecutivoDr. Paul B. Bolno, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
40.39K
+150.62%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
+78.81%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
19.14K
+18.80%
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
40.39K
+150.62%
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
+78.81%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+48.58%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
19.14K
+18.80%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 15 de may
Actualizado: jue., 15 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
5.50%
Maverick Capital, Ltd.
5.19%
Otro
57.91%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
9.43%
BlackRock Institutional Trust Company, N.A.
5.50%
Maverick Capital, Ltd.
5.19%
Otro
57.91%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
31.43%
Hedge Fund
24.51%
Investment Advisor/Hedge Fund
16.55%
Corporation
15.30%
Venture Capital
11.51%
Research Firm
2.29%
Individual Investor
0.49%
Bank and Trust
0.29%
Pension Fund
0.25%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
364
156.69M
98.46%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
2023Q3
224
93.79M
97.86%
+5.83M
2023Q2
224
93.41M
97.80%
+7.66M
2023Q1
249
91.33M
96.13%
+7.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
18.20M
11.7%
--
--
Mar 31, 2025
GSK plc
16.78M
10.78%
--
--
Jun 06, 2025
Adage Capital Management, L.P.
12.52M
8.05%
+2.89M
+30.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
5.28%
+200.47K
+2.50%
Mar 31, 2025
Maverick Capital, Ltd.
8.26M
5.31%
+441.00
+0.01%
Mar 31, 2025
Driehaus Capital Management, LLC
6.36M
4.09%
-353.85K
-5.27%
Mar 31, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.67%
--
--
Jun 06, 2025
M28 Capital Management LP
5.66M
3.64%
--
--
Mar 31, 2025
Emerald Advisers LLC
5.06M
3.26%
-29.02K
-0.57%
Mar 31, 2025
T. Rowe Price Associates, Inc.
4.03M
2.59%
-969.83K
-19.40%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
iShares Health Innovation Active ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Vanguard US Momentum Factor ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
Avantis US Equity ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Ver más
iShares Health Innovation Active ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Vanguard US Momentum Factor ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporción0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
iShares Neuroscience and Healthcare ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
